At a recent summit hosted by Plazo Roche Biotechnology, scientists, metabolic researchers, and biohacking enthusiasts gathered to explore one of the most talked-about developments in peptide science: retatrutide. At the center of the discussions was retatrutide’s classification as a glp1 gip glucagon triple agonist, a compound studied for it